Phase 2 results on Atea/Roche #covid19 antiviral AT-527 just out. Didn't meet goal in reducing virus in mild to moderate Covid in overall study population, which co says was 2/3 patients at low risk w mild symptoms. But says there was a reduction for high-risk patients (1/2)
Atea says it and Roche are assessing modifications to their phase 3 #covid19 antiviral trial, and now expect results from it in the second half of 2022 (2/2)
ir.ateapharma.com/news-releases/…
ir.ateapharma.com/news-releases/…
Shares of Atea ($AVIR) are down 65% pre-market after a trading halt
Atea notes its #covid19 antiviral study participants (2/3 of whom had no underlying health conditions) were on average 37 years old, & included people who were vaccinated.
(Merck study of molnupiravir focused on patients at high risk, and nobody was vaccinated in trial.)
(Merck study of molnupiravir focused on patients at high risk, and nobody was vaccinated in trial.)
Evercore ISI analyst Umer Raffat says Atea/Roche antiviral didn't "fail" in phase 2 - says it's just the trial design that disappointed.
Umer says viral load benefit seen in high-risk subgroup "is comparable to MRK"
If so, disappointing this won't be available for at least a yr
Umer says viral load benefit seen in high-risk subgroup "is comparable to MRK"
If so, disappointing this won't be available for at least a yr
• • •
Missing some Tweet in this thread? You can try to
force a refresh
